Partnership agreements are a key part of NicOx’s business strategy, allowing the Company to focus on its lead products, while maximizing the value of its portfolio of development compounds in non-core therapeutic areas.

NicOx’s partners are chosen based on their expertise and commitment to research and development in areas that are outside of NicOx’s core focus on inflammation and cardiovascular diseases.

These co-development agreements provide NicOx with a broad and differentiated pipeline. 

In June 2001, NicOx signed a research and co-development agreement on a novel class of nitric oxide-donating respiratory therapeutics with Biolipox, a Swedish company. In November 2007, Orexo AB another Swedish specialty pharmaceutical company acquired Biolipox AB.

This partnership has not resulted in significant developments and accordingly NicOx and Orexo AB are currently considering alternatives for its termination.